Amarin Corporation plc announced that the Greek Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (= 150 mg/ml [= 1.7 mmol/l) and established cardiovascular disease, or diabetes and at least one other cardiovascular risk factor1. As in most European countries, cardiovascular diseases are the main cause of death in Greece2. Today?s approval ?

which marks the seventh national reimbursement of VAZKEPA® in Europe ? provides eligible patients across Greece access to a new treatment option to reduce their cardiovascular risk and help improve their overall heart health.